MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublikationen in Zusammenarbeit mit Forschern von Fondazione IRCCS Istituto Nazionale dei Tumori (5)
2019
-
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)
Clinical Colorectal Cancer, Vol. 18, Núm. 3, pp. 183-191.e3
-
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435
2018
-
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet, Vol. 392, Núm. 10142, pp. 123-133
2016
-
Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
Annals of Oncology, Vol. 27, pp. vi182
-
Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview
Annals of Oncology, Vol. 27, pp. vi169